Literature DB >> 18543112

Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Bo Wang1, Roland Tisch.   

Abstract

Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin producing beta cells are destroyed. Antigen-based immunotherapy provides an approach to selectively tolerize pathogenic beta cell-specific T cells, while leaving the remainder of the immune system intact. In this chapter, we discuss our group's experience in defining the parameters that impact the efficacy of beta cell antigen "vaccination" for the prevention and treatment of T1D.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18543112     DOI： 10.1007/s12026-008-8020-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  115 in total

Review 1.  Prediction of type 1 diabetes: the natural history of the prediabetic period.

Authors:  George S Eisenbarth
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

2.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

Review 3.  T cell tolerance induced by therapeutic antibodies.

Authors:  Stephen P Cobbold
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera.

Authors:  Sofia Casares; Alicia Hurtado; Robert C McEvoy; Adelaida Sarukhan; Harald von Boehmer; Teodor-Doru Brumeanu
Journal:  Nat Immunol       Date:  2002-02-25       Impact factor: 25.606

5.  More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice.

Authors:  Christian Seifarth; Shannon Pop; Bo Liu; Carmen P Wong; Roland Tisch
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

6.  Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes.

Authors:  Shannon M Pop; Carmen P Wong; Donna A Culton; Stephen H Clarke; Roland Tisch
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

7.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

8.  In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.

Authors:  S V Pakala; M Chivetta; C B Kelly; J D Katz
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

9.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

Authors:  Kristin V Tarbell; Sayuri Yamazaki; Kara Olson; Priscilla Toy; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307
View more
  3 in total

1.  GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.

Authors:  Camilla Skoglund; Mikael Chéramy; Rosaura Casas; Johnny Ludvigsson; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2011-08-16       Impact factor: 4.866

2.  Oral delivery of the intracellular domain of the insulinoma-associated protein 2 (IA-2ic) by bacterium-like particles (BLPs) prevents type 1 diabetes mellitus in NOD mice.

Authors:  Ruifeng Mao; Menglan Yang; Rui Yang; Yingying Chen; Enjie Diao; Tong Zhang; Dengchao Li; Xin Chang; Zhenjing Chi; Yefu Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Tolerogenic vaccination reduced effector memory CD4 T cells and induced effector memory Treg cells for type I diabetes treatment.

Authors:  Jingyao Zhang; Wenjuan Gao; Xu Yang; Jingjing Kang; Yongliang Zhang; Qirui Guo; Yanxin Hu; Guoliang Xia; Youmin Kang
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.